ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Alemtuzumab: Drug information

Alemtuzumab: Drug information
2024© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Alemtuzumab: Patient drug information"

For abbreviations, symbols, and age group definitions show table
ALERT: US Boxed Warning
Bone marrow suppression (Campath):

Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving alemtuzumab. Single doses of alemtuzumab >30 mg or cumulative doses >90 mg per week increase the incidence of pancytopenia.

Infusion reactions (Campath):

Alemtuzumab administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold alemtuzumab for Grade 3 or 4 infusion reactions. Gradually escalate alemtuzumab to the recommended dose at the initiation of therapy and after interruption of therapy for ≥7 days.

Infections (Campath):

Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving alemtuzumab. Administer prophylaxis against Pneumocystis jirovecii pneumonia and herpes virus infections.

Autoimmune effects (Lemtrada):

Alemtuzumab causes serious, sometimes fatal, autoimmune conditions, such as immune thrombocytopenia and anti-glomerular basement membrane disease. Monitor CBC with differential, serum creatinine levels, and urinalysis with urine cell counts before starting treatment and then at monthly intervals until 48 months after the last dose of alemtuzumab.

Infusion reactions (Lemtrada):

Alemtuzumab causes serious and life-threatening infusion reactions. Alemtuzumab must be administered in a setting with appropriate equipment and personnel to manage anaphylaxis or serious infusion reactions. Monitor patients for 2 hours after each infusion. Make patients aware that serious infusion reactions can also occur after the 2-hour monitoring period.

Malignancy (Lemtrada):

Alemtuzumab may cause an increased risk of malignancies, including thyroid cancer, melanoma, and lymphoproliferative disorders. Perform baseline and yearly skin exams.

REMS program (Lemtrada):

Because of the risk of autoimmunity, infusion reactions, and malignancies, Lemtrada is available only through restricted distribution under a Risk Evaluation Mitigation Strategy (REMS) Program. Call 1-855-676-6326 to enroll in the Lemtrada REMS program.

Stroke (Lemtrada):

Serious and life-threatening stroke (including ischemic and hemorrhagic stroke) has been reported within 3 days of alemtuzumab administration. Instruct patients to seek immediate medical attention if symptoms of stroke occur.

Brand Names: US
  • Lemtrada
Brand Names: Canada
  • Lemtrada;
  • MabCampath
Pharmacologic Category
  • Antineoplastic Agent, Anti-CD52;
  • Antineoplastic Agent, Monoclonal Antibody;
  • Monoclonal Antibody
Dosing: Adult

Note: Premedications are recommended. Alemtuzumab is associated with a moderate emetic potential in the oncology setting; antiemetics may be recommended to prevent nausea and vomiting (Ref). Prophylaxis against opportunistic infections should be implemented based on indication and patient specific factors. For oncology indications, Pneumocystis jirovecii pneumonia (PCP) prophylaxis is recommended during alemtuzumab treatment and for at least 2 months following last dose or until CD4+ counts are ≥200/mm3 (whichever is later). For oncology indications and multiple sclerosis, herpes virus prophylaxis is recommended during alemtuzumab treatment and for at least 2 months following last dose or until CD4+ counts are ≥200 mm3 (whichever is later).

B-cell chronic lymphocytic leukemia

B-cell chronic lymphocytic leukemia (CLL): Campath, MabCampath [Canadian product]: IV: Gradually escalate to a maintenance of 30 mg per dose 3 times weekly on alternate days for a total duration of therapy of up to 12 weeks (Ref).

Note: Dose escalation is required; usually accomplished in 3 to 7 days. Single doses >30 mg or cumulative doses >90 mg/week increase the incidence of pancytopenia. Pretreatment (with acetaminophen 500 to 1,000 mg and diphenhydramine 50 mg) is recommended 30 minutes prior to the first dose, with dose escalations, and as clinically indicated; IV glucocorticoids may be used for severe infusion-related reactions. Administer antiviral prophylaxis (for herpetic viral infections) and PCP prophylaxis; continue for at least 2 months after completion of alemtuzumab and until CD4+ lymphocyte count is ≥200/mm3. Reinitiate with gradual dose escalation if treatment is withheld ≥7 days.

Dose escalation: IV: Initial: 3 mg daily beginning on day 1; if tolerated (infusion reaction ≤ grade 2), increase to 10 mg daily; if tolerated (infusion reaction ≤ grade 2), may increase to maintenance of 30 mg per dose 3 times weekly (on alternate days) if required.

B-cell CLL (off-label route): Campath: SUBQ: Initial: 3 mg on day 1; if tolerated 10 mg on day 3; if tolerated increase to 30 mg on day 5; maintenance: 30 mg per dose 3 times weekly on alternate days for a maximum of 18 weeks (Ref) or 3 mg on day 1; if tolerated 10 mg on day 2; if tolerated 30 mg on day 3, followed by 30 mg per dose 3 times weekly on alternate days for 4 to 12 weeks (Ref).

Multiple sclerosis, relapsing

Multiple sclerosis, relapsing:

Note: Safety: In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other appropriate specialists (eg, liver specialists) regarding treatment options before initiating therapy (Ref). Administer antiviral prophylaxis (for herpetic viral infections) beginning on the first day of treatment and continue for at least 2 months after completion of alemtuzumab or until CD4+ lymphocyte count is ≥200/mm3 (whichever occurs later). Premedication: Premedicate with corticosteroids (methylprednisolone 1 g or equivalent) immediately prior to alemtuzumab for the first 3 days of each treatment course. Antihistamines and/or antipyretics may also be considered.

Lemtrada: IV: 12 mg daily for 5 consecutive days (total 60 mg), followed 12 months later by 12 mg daily for 3 consecutive days (total 36 mg). Subsequent treatment courses of 12 mg daily for 3 consecutive days (total 36 mg) may be administered if necessary; courses should be administered no earlier than 12 months after the last dose of the prior treatment cycle.

Aplastic anemia, refractory

Aplastic anemia, refractory (off-label use): Campath:

IV: 10 mg daily for 10 days (as monotherapy); patients received a 1 mg test dose initially (Ref) or

SUBQ: 3 mg day 1, 10 mg day 2, then 30 mg/day days 3, 4, and 5 (total dose: 103 mg over 5 consecutive days; in combination with cyclosporine) (Ref).

Autoimmune cytopenias, chronic lymphocytic leukemia induced, refractory

Autoimmune cytopenias, chronic lymphocytic leukemia induced, refractory (off-label use): Campath: IV, SUBQ: Gradually escalate to a maintenance of 10 to 30 mg per dose 3 times weekly for 4 to 12 weeks (Ref).

Graft-versus-host disease, acute, steroid refractory, treatment

Graft-versus-host disease, acute, steroid refractory, treatment (off-label use): Campath: IV: 10 mg daily for 5 consecutive days, then 10 mg weekly on days 8, 15, and 22 if CR not achieved (Ref) or 10 mg weekly until symptom resolution (Ref).

Hematopoietic cell transplant conditioning regimen

Hematopoietic cell transplant (allogeneic) conditioning regimen (off-label use): Campath: IV: 20 mg daily for 5 days (in combination with fludarabine and melphalan) beginning 8 days prior to transplant (Ref) or beginning 7 days prior to transplant (Ref).

Hemophagocytic lymphohistiocytosis, refractory

Hemophagocytic lymphohistiocytosis, refractory (off-label use): Campath: Note: The optimal dose and duration of therapy is not known. Median dose: IV, SUBQ: 1 mg/kg (range 0.1 to 8.9 mg/kg; maximum initial dose: 3 mg) divided over a median of 4 days (range 2 to 10 days); refer to article for further information (Ref).

Mycosis fungoides/Sézary syndrome, advanced

Mycosis fungoides/Sézary syndrome, advanced (off-label use): Campath: IV: Initial: 3 mg, increase to 10 mg and then to 30 mg as soon as infusion-related reactions were tolerated; Maintenance: 30 mg 3 times weekly for up to 12 weeks, or until complete remission is achieved or disease progression is noted; for dosing interruptions >7 days due to toxicity, reinitiate at 3 or 10 mg (Ref).

Solid organ transplantation

Solid organ transplantation: Campath:

Heart transplant, induction (off-label use): IV: 30 mg once intra-operatively at the time of transplant followed by minimized maintenance immunosuppression (Ref).

Intestine transplant, induction (off-label use): Note: Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen. An example regimen is provided.

IV: 30 mg administered intraoperatively at induction of anesthesia for the transplant procedure (Ref).

Kidney transplant, induction (off-label use): IV: 30 mg as a single dose at the time of transplant (immediately following reperfusion) followed by a second 30 mg dose 24 hours later (the second dose was omitted in patients >60 years of age); followed by minimized maintenance immunosuppression (Ref).

Kidney transplant, steroid-resistant cellular rejection (off-label use): IV, SUBQ: 15 to 30 mg/dose SUBQ on 2 subsequent days (Ref) or 30 mg/dose IV over 2 to 4 hours for 1 to 2 doses (Ref).

Lung transplant, induction (off-label use): IV, SUBQ: 30 mg once either immediately before allograft reperfusion or immediately following transplant; followed by minimized maintenance immunosuppression (Ref).

Lung transplant, refractory rejection, treatment (adjunctive) (off-label use): Note: Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen. An example regimen is provided.

IV: 30 mg administered as a single dose (Ref).

Multivisceral transplant, induction (off-label use): Note: Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen. An example regimen is provided.

IV: 30 mg administered intraoperatively at induction of anesthesia for the transplant procedure (Ref).

Pancreas transplant, induction (off-label use): Note: Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen. An example regimen is provided.

IV: 30 mg administered intraoperatively during the transplant procedure (Ref).

T-cell large granular lymphocytic leukemia

T-cell large granular lymphocytic leukemia (off-label use): Campath: IV: 10 mg daily for 10 days; patients received a 1 mg test dose initially (Ref).

T-cell prolymphocytic leukemia

T-cell prolymphocytic leukemia (off-label use): Campath:

Refractory disease: IV: Initial test dose 3 mg or 10 mg, followed by dose escalation to 30 mg per dose 3 times weekly as tolerated until maximum response (Ref) or Initial dose: 3 mg on day 1, if tolerated increase to 10 mg on day 2, if tolerated increase to 30 mg on day 3 (days 1, 2, and 3 are consecutive days), followed by 30 mg per dose every Monday, Wednesday, Friday for a total of 4 to 12 weeks (Ref).

Consolidation (following FMC [fludarabine, mitoxantrone, and cyclophosphamide] induction chemotherapy): Initial dose: IV: 3 mg on day 1, if tolerated increase to 10 mg on day 2, if tolerated increase to 30 mg on day 3, followed by 30 mg per dose 3 times a week for up to 12 weeks (Ref). Refer to protocol for FMC cycle details, when alemtuzumab is initiated, and monitoring.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Obesity: Adult

American Society for Blood and Marrow Transplantation practice guideline committee position statement on chemotherapy dosing in adults with a BMI ≥30 kg/m2: Utilize a flat dose based on the regimen selected for hematopoietic cell transplant conditioning in adults (Ref).

Dosing: Adjustment for Toxicity: Adult

Dosage adjustment for nonhematologic toxicity:

Treatment of B-CLL: Campath, MabCampath [Canadian product]:

Note: If treatment is withheld ≥7 days, reinitiate at 3 mg with re-escalation to 10 mg and then 30 mg.

Grade 3 or 4 infusion reaction: Withhold infusion; medications for the treatment of infusion reactions should be available for immediate use.

Infection, serious: Withhold alemtuzumab until resolution; may be reinitiated upon resolution of infection. For cytomegalovirus (CMV) infection or confirmed CMV viremia, withhold alemtuzumab and initiate appropriate antiviral treatment.

Autoimmune anemia or autoimmune thrombocytopenia: Discontinue alemtuzumab.

Other serious adverse reaction: Withhold alemtuzumab until resolution.

Treatment of MS: Lemtrada:

Adult-onset Still disease: Discontinue alemtuzumab if alternate etiology cannot be established.

Serious infusion reaction: Consider immediate discontinuation.

Dosage adjustment for hematologic toxicity (severe neutropenia or thrombocytopenia, not autoimmune): Treatment of B-CLL: Campath, MabCampath [Canadian product]:

Note: If treatment is withheld ≥7 days, reinitiate at 3 mg with re-escalation to 10 mg and then 30 mg.

ANC <250/mm3 and/or platelet count ≤25,000/mm3:

First occurrence: Withhold treatment; resume at 30 mg per dose when ANC ≥500/mm3 and platelet count ≥50,000/mm3.

Second occurrence: Withhold treatment; resume at 10 mg per dose when ANC ≥500/mm3 and platelet count ≥50,000/mm3.

Third occurrence: Discontinue alemtuzumab.

Patients with a baseline ANC ≤250/mm3 and/or a baseline platelet count ≤25,000/mm3 at initiation of therapy: If ANC and/or platelet counts decrease by ≥50% of the baseline value:

First occurrence: Withhold treatment; resume at 30 mg per dose upon return to baseline values.

Second occurrence: Withhold treatment; resume at 10 mg per dose upon return to baseline values.

Third occurrence: Discontinue alemtuzumab.

Hemophagocytic lymphohistiocytosis: Discontinue alemtuzumab if alternate etiology of signs/symptoms cannot be established.

Thrombotic thrombocytopenic purpura: Discontinue alemtuzumab if thrombotic thrombocytopenic purpura is confirmed or if alternate etiology of signs/symptoms cannot be established.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric
Aplastic anemia, refractory

Aplastic anemia, refractory (off-label use): Campath:

Children ≥2 years of age and Adolescents (<50 kg): IV: 0.2 mg/kg/dose (maximum: 10 mg/dose) for 10 days (as monotherapy); patients received a 1 mg test dose initially (Ref)

Children ≥2 years of age and Adolescents (≥50 kg): IV: 10 mg daily for 10 days (as monotherapy); patients received a 1 mg test dose initially (Ref)

Hemophagocytic lymphohistiocytosis, refractory

Hemophagocytic lymphohistiocytosis, refractory (off-label use): Infants, Children, and Adolescents: Campath: IV, SubQ: Note: The optimal dose and duration of therapy is not known. Median dose: 1 mg/kg (range 0.1 to 8.9 mg/kg; maximum initial dose: 3 mg) divided over a median of 4 days (range 2 to 10 days); refer to article for further information (Ref)

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing adjustment for toxicity: There are no pediatric-specific recommendations; the presented dosing adjustments are based on experience in adult patients. Refer to specific protocol for management in pediatric patients if available.

Nonhematologic toxicity:

Treatment of B-CLL: Campath, MabCampath [Canadian product]:

Note: If treatment is withheld ≥7 days, reinitiate at 3 mg with re-escalation to 10 mg and then 30 mg.

Grade 3 or 4 infusion reaction: Withhold infusion

Serious infection or other serious adverse reaction: Withhold alemtuzumab until resolution

Autoimmune anemia or autoimmune thrombocytopenia: Discontinue alemtuzumab

Hematologic toxicity (severe neutropenia or thrombocytopenia, not autoimmune): Treatment of B-CLL: Campath, MabCampath [Canadian product]:

Note: If treatment is withheld ≥7 days, reinitiate at 3 mg with re-escalation to 10 mg and then 30 mg.

ANC <250/mm3 and/or platelet count ≤25,000/mm3:

First occurrence: Withhold treatment; resume at 30 mg per dose when ANC ≥500/mm3 and platelet count ≥50,000/mm3

Second occurrence: Withhold treatment; resume at 10 mg per dose when ANC ≥500/mm3 and platelet count ≥50,000/mm3

Third occurrence: Discontinue alemtuzumab.

Patients with a baseline ANC ≤250/mm3 and/or a baseline platelet count ≤25,000/mm3 at initiation of therapy: If ANC and/or platelet counts decrease by ≥50% of the baseline value:

First occurrence: Withhold treatment; resume at 30 mg per dose upon return to baseline values

Second occurrence: Withhold treatment; resume at 10 mg per dose upon return to baseline values

Third occurrence: Discontinue alemtuzumab.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.

Multiple sclerosis:

>10%:

Dermatologic: Pruritus (14%), skin rash (53%), urticaria (16%)

Endocrine & metabolic: Thyroid disease (13% to 37%)

Gastrointestinal: Diarrhea (12%), nausea (21%)

Genitourinary: Urinary tract infection (19%)

Hematologic & oncologic: Lymphocytopenia (100%)

Hypersensitivity: Infusion-related reaction (92%; severe infusion-related reaction: 3%)

Immunologic: Antibody development (neutralizing: 5% to 94%; anti-alemtuzumab: 29% to 83%; no significant effect on drug efficacy)

Infection: Fungal infection (12% to 13%, including oral candidiasis, vulvovaginal candidiasis), herpes virus infection (16%), infection (71%; serious infection: 3%)

Nervous system: Fatigue (18%), headache (52%), insomnia (16%)

Neuromuscular & skeletal: Arthralgia (12%), back pain (12%), limb pain (12%)

Respiratory: Nasopharyngitis (25%), oropharyngeal pain (11%), sinusitis (11%), upper respiratory tract infection (16%)

Miscellaneous: Fever (29%)

1% to 10%:

Cardiovascular: Chest discomfort (7%), flushing (10%), peripheral edema (5%), tachycardia (8%)

Dermatologic: Dermatitis (8%), erythema of skin (5%)

Gastrointestinal: Abdominal pain (10%), appendicitis (≤3%), dysgeusia (8%), dyspepsia (8%), gastroenteritis (≤3%), oral herpes simplex infection (9%), tooth infection (≤3%), vomiting (10%)

Genitourinary: Abnormal uterine bleeding (5%), genital herpes simplex (1%), microscopic hematuria (8%)

Hematologic & oncologic: Decreased CD-4 cell count (6%), decreased CD-8 cell counts (6%), decreased T-cell lymphocytes (5%), immune thrombocytopenia (2%)

Hypersensitivity: Angioedema (≤3%)

Infection: Herpes simplex infection (2%), herpes zoster infection (4%), human papilloma virus infection (2%), influenza (8%)

Nervous system: Anxiety (7%), asthenia (5%), chills (9%), dizziness (10%), myasthenia (7%), paresthesia (10%)

Neuromuscular & skeletal: Muscle spasm (6%), myalgia (6%), neck pain (5%)

Ophthalmic: Graves ophthalmopathy (2%)

Respiratory: Bronchitis (7%), cough (9%), dyspnea (8%), epistaxis (5%), pneumonia (≤3%)

<1%:

Dermatologic: Malignant melanoma, vitiligo

Endocrine & metabolic: Thyroid neoplasm, type 1 diabetes mellitus

Hematologic & oncologic: Acquired blood coagulation disorder (hemophilia A [anti-Factor VIII antibodies]), hemolytic anemia (including autoimmune hemolytic anemia), neutropenia, pancytopenia

Hypersensitivity: Anaphylactic shock, anaphylaxis

Immunologic: Anti-GBM disease

Infection: Varicella zoster infection

Nervous system: Meningitis (herpes), suicidal ideation, suicidal tendencies

Neuromuscular & skeletal: Connective tissue disease (undifferentiated), rheumatoid arthritis

Ophthalmic: Retinal pigment changes (epitheliopathy)

Renal: Membranous glomerulonephritis

Respiratory: Pneumonitis (including with fibrosis), tuberculosis

Frequency not defined:

Endocrine & metabolic: Goiter, Graves disease, hyperthyroidism, hypothyroidism, thyroiditis

Nervous system: Pain

Respiratory: Hypersensitivity pneumonitis

B-cell chronic lymphocytic leukemia:

>10%:

Cardiovascular: Cardiac arrhythmia (14%), hypertension (14%), hypotension (16%)

Dermatologic: Skin rash (13%), urticaria (16%)

Hematologic & oncologic: Anemia (76%; grades 3/4: 12% to 38%), lymphocytopenia (97%; grades 3/4: 97%), neutropenia (77%; grades 3/4: 42% to 64%), thrombocytopenia (71%; grades 3/4: 13% to 52%)

Hypersensitivity: Infusion-related reaction (more frequently seen in the first week of treatment)

Infection: CMV viremia (55%), cytomegalovirus disease (6% to 16%), infection (50% to 74%)

Nervous system: Chills (53%), headache (14%)

Respiratory: Dyspnea (14%)

Miscellaneous: Fever (69%)

1% to 10%:

Cardiovascular: Tachycardia (10%)

Dermatologic: Erythema of skin (4%)

Gastrointestinal: Anorexia (>5%), diarrhea (10%), nausea (>5%), stomatitis (>5%), vomiting (>5%)

Hematologic & oncologic: Autoimmune thrombocytopenia (2%), febrile neutropenia (grades ≥3: 5% to 10%)

Immunologic: Antibody development (2% to 8%; neutralizing: 2%)

Infection: Sepsis (grades ≥3: 3% to 10%)

Nervous system: Anxiety (8%), dysesthesia (>5%), fatigue (>5%), insomnia (10%), tremor (3%)

Neuromuscular & skeletal: Musculoskeletal pain (>5%)

Respiratory: Bronchospasm (>5%)

Frequency not defined: Gastrointestinal: Abdominal pain

Postmarketing (all indications):

Cardiovascular: Acute myocardial infarction, cardiac insufficiency (acute), cardiomyopathy, coronary artery dissection (cervicocephalic arterial dissection [vertebral, carotid]), heart failure, ischemic heart disease, reduced ejection fraction, syncope, vasculitis

Dermatologic: Alopecia

Gastrointestinal: Cholecystitis (calculous and acalculous)

Hematologic & oncologic: Aplastic anemia, bone marrow aplasia, bone marrow depression (prolonged), hemophagocytic lymphohistiocytosis, lymphoproliferative disorder, malignant lymphoma, pure red cell aplasia, thrombotic thrombocytopenic purpura, tumor lysis syndrome

Hepatic: Autoimmune hepatitis, viral hepatitis

Hypersensitivity: Serum sickness

Immunologic: Epstein-Barr-associated lymphoproliferative disorder, graft-versus-host disease (transfusion associated), sarcoidosis

Infection: Epstein-Barr infection, listeriosis (including gastroenteritis, encephalitis, sepsis), opportunistic infection (including aspergillosis, coccidioidomycosis, histoplasmosis, nocardiosis)

Nervous system: Cerebrovascular accident, chronic inflammatory demyelinating polyneuropathy, encephalitis (autoimmune), Guillain-Barré syndrome, intracranial hemorrhage, ischemic stroke, meningitis due to Listeria monocytogenes, myasthenia gravis, progressive multifocal leukoencephalopathy

Neuromuscular & skeletal: Arthritis (adult-onset Still disease), Lambert-Eaton syndrome

Ophthalmic: Optic neuropathy

Respiratory: Acute respiratory distress syndrome, apnea, pneumonia due to Pneumocystis jirovecii, pulmonary alveolar hemorrhage, pulmonary infiltrates

Miscellaneous: Reactivation of disease

Contraindications

US labeling: Hypersensitivity (eg, anaphylactic reactions) to alemtuzumab or any component of the formulation; HIV infection (due to prolonged reduction in CD4+ lymphocytes); active infection. There are no contraindications listed in the manufacturer's Campath labeling.

Canadian labeling:

Lemtrada: Hypersensitivity to alemtuzumab or any component of the formulation; HIV infection; tuberculosis (TB) disease (active TB) or infection (latent TB); severe active infections; active malignancies; concurrent anticoagulant, antiplatelet, antineoplastic, or immunosuppressive therapy; history of progressive multifocal leukoencephalopathy (PML); history of stroke and arterial dissection of cervicocephalic arteries; uncontrolled hypertension; history of angina or myocardial infarction; known coagulopathy.

MabCampath: Known type 1 hypersensitivity or anaphylactic reactions to alemtuzumab or any component of the formulation; active infections; underlying immunodeficiency (eg, seropositive for HIV); active secondary malignancies; current or history of PML.

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Warnings/Precautions

Concerns related to adverse effects:

• Adult-onset Still disease: Rare cases of adult-onset Still disease have been reported in patients receiving alemtuzumab for multiple sclerosis. Promptly evaluate patients with signs and symptoms (eg, fever, arthritis, rash, leukocytosis in the absence of infections, malignancies, or other rheumatic conditions) suggestive of adult-onset Still disease.

• Autoimmune effects: [US Boxed Warning (Lemtrada)]: Alemtuzumab causes serious, sometimes fatal, autoimmune conditions, such as immune thrombocytopenia and antiglomerular basement membrane (anti-GBM) disease, in patients receiving alemtuzumab for the treatment of multiple sclerosis (MS). Monitor CBC with differential, serum creatinine levels, and urinalysis with urine cell counts before starting treatment and then at monthly intervals until 48 months after the last dose of alemtuzumab. Monitor for symptoms of immune thrombocytopenia (easy bruising, petechiae, spontaneous mucocutaneous bleeding, heavy menstrual bleeding) in patients receiving alemtuzumab for MS. Glomerular nephropathies, including anti-GBM disease, have been reported up to 40 months after the last dose. Monitor for nephropathy symptoms (dyspnea, edema, elevated serum creatinine, change in urine color, decreased urine output, fatigue, hematuria, hemoptysis, proteinuria). Glomerular nephropathies require urgent evaluation; may lead to end-stage renal disease requiring dialysis or renal transplantation if not treated. Urine dipstick results of ≥1+ protein warrant assessment of urine protein to creatinine ratio. Perform further evaluation for nephropathies if urine protein to creatinine ratio >200 mg/g, increase in serum creatinine >30%, or unexplained hematuria. Alveolar hemorrhage manifesting as hemoptysis has been reported with anti-GBM disease. Prompt intervention is necessary for increased serum creatinine with hematuria, signs of pulmonary involvement of anti-GBM disease (eg, hemoptysis, exertional dyspnea), or autoimmune cytopenias. Immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura), thrombotic thrombocytopenic purpura (TTP), thyroid disorders, autoimmune encephalitis, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune pancytopenia, undifferentiated connective tissue disorders, acquired hemophilia A, rheumatoid arthritis, type 1 diabetes, vasculitis, vitiligo, and retinal pigment epitheliopathy have been reported in patients receiving alemtuzumab for MS. Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy have been reported in patients receiving alemtuzumab for other uses. Alemtuzumab may increase the risk for other autoimmune conditions.

• Autoimmune encephalitis: Autoimmune encephalitis, including signs and symptoms of altered mental status, subacute onset of memory impairment, neurological findings, psychiatric symptoms, and seizures, has been reported. Discontinue therapy if autoimmune encephalitis is suspected or confirmed by the presence of neural autoantibodies.

• Bone marrow suppression: [US Boxed Warning (Campath)]: Serious and fatal cytopenias (including pancytopenia, bone marrow hypoplasia, autoimmune hemolytic anemia, and autoimmune idiopathic thrombocytopenia) have occurred. Single doses >30 mg or cumulative weekly doses >90 mg are associated with an increased incidence of pancytopenia. Severe prolonged myelosuppression, hemolytic anemia, pure red cell aplasia, bone marrow aplasia, and bone marrow hypoplasia have also been reported with use at the normal dose for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). Discontinue for serious hematologic or other serious toxicity (except lymphopenia) until the event resolves. Permanently discontinue if autoimmune anemia or autoimmune thrombocytopenia occurs. Patients receiving blood products should only receive irradiated blood products due to the potential for transfusion-associated graft-versus-host disease during lymphopenia.

• Cholecystitis: In a clinical trial of patients with MS, an increased risk of acute acalculous cholecystitis was observed in patients receiving alemtuzumab versus interferon beta-1a; additional postmarketing cases have also been reported. Symptom onset ranged from <24 hours to 2 months after alemtuzumab infusion. Some patients recovered without surgical intervention (and received antibiotics); some patients underwent cholecystectomy. Monitor closely (acute acalculous cholecystitis is associated with high morbidity and mortality); symptoms may include abdominal pain/tenderness, fever, nausea, vomiting, leukocytosis, and abnormal liver enzymes. Evaluate and treat promptly if acute acalculous cholecystitis is suspected or diagnosed.

• Hemophagocytic lymphohistiocytosis: Hemophagocytic lymphohistiocytosis (HLH), a life-threatening immune system reaction, has been reported with alemtuzumab use and is associated with high mortality rates if not treated early; it is characterized by clinical signs and symptoms of extreme systemic inflammation. Symptoms may include fever, rash, hepatosplenomegaly, lymphadenopathy, neurologic symptoms, cytopenias, elevated serum ferritin, hypertriglyceridemia, and liver function and coagulation abnormalities. Symptoms of HLH have been reported to occur up to 33 months following initiation of treatment.

• Hemophilia: Acquired hemophilia A (anti-factor VIII antibodies) has been reported. Symptoms have included spontaneous subcutaneous hematomas and extensive bruising; epistaxis, GI bleeding, hematuria, and other types of bleeding may also occur. Coagulopathy panel including aPTT should be obtained if acquired hemophilia is suspected. Patients should seek medical attention for signs and symptoms of acquired hemophilia A.

• Hepatitis: Autoimmune hepatitis causing clinically significant liver injury, including acute liver failure requiring transplant, has been reported; monitor serum transaminases and total bilirubin prior to initiation of therapy, then periodically until 48 months after the last infusion or at any time during therapy. Monitor for clinical signs/symptoms of hepatic dysfunction (unexplained nausea, vomiting, abdominal pain, anorexia, fatigue, jaundice, and/or dark urine); if reported, promptly obtain serum transaminases and total bilirubin; may require treatment interruption or discontinuation.

• Infections: [US Boxed Warning (Campath)]: Serious and potentially fatal infections (bacterial, viral, fungal, and protozoan) have been reported. Administer prophylactic medications against Pneumocystis jirovecii pneumonia (PCP) and herpes viral infections during treatment and for at least 2 months following last dose or until CD4+ counts are ≥200 cells/mm3 (whichever is later). Severe and prolonged lymphopenia may occur; CD4+ counts usually return to ≥200 cells/mm3 within 2 to 6 months; however, CD4+ and CD8+ lymphocyte counts may not return to baseline levels for more than 1 year. Withhold treatment during serious infections; may be reinitiated upon resolution of infection. Monitor for cytomegalovirus (CMV) infection (during and for at least 2 months after completion of therapy); initiate appropriate antiviral treatment and withhold alemtuzumab for CMV infection or confirmed CMV viremia (withhold alemtuzumab during CMV antiviral treatment). For patients being treated for MS, initiate antiviral prophylaxis (for herpetic viral infections) beginning on the first day of treatment and continue for at least 2 months or until CD4+ lymphocyte count is ≥200/mm3. In clinical trials for MS, infections seen more commonly in alemtuzumab-treated patients included nasopharyngitis, urinary tract infection, upper respiratory tract infection, sinusitis, herpetic infections, influenza, and bronchitis; serious cases of appendicitis, gastroenteritis, pneumonia, herpes zoster, and tooth infection also occurred. Serious (sometimes fatal) opportunistic infections have been reported, including aspergillosis, coccidioidomycosis, histoplasmosis, PCP, nocardiosis, Epstein-Barr virus, and CMV. Listeria monocytogenes infections (encephalitis, gastroenteritis, meningitis, sepsis), including fatal cases of Listeria meningoencephalitis have been reported; Listeria infections have developed as early as 3 days post treatment and up to 8 months after the last dose for MS. The duration of increased risk for Listeria infections after treatment is unknown. Patients should initiate Listeria precautions prior to starting treatment, which include avoiding or adequately heating foods that may potentially carry this bacteria (eg, deli meat, dairy products made with unpasteurized milk, soft cheeses, or undercooked meat, seafood, or poultry). The incubation period for Listeria monocytogenes ranges from 3 to 70 days; signs/symptoms of invasive listeriosis generally start within 1 month of exposure. Symptoms of Listeria infection include fever, chills, diarrhea, nausea, vomiting, headache, pains in joints and muscles, neck stiffness, difficulty walking, mental status changes, coma, and other neurologic changes. Treatment (eg, with anti-infectives) may not adequately prevent Listeria infection-related morbidity/mortality. Epstein-Barr virus (EBV), including severe and fatal EBV-associated hepatitis, has been reported; monitor for signs and symptoms of EBV infection. Consider delaying treatment in patients with any active infection or EBV reactivation until infection is controlled. In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other specialists (eg, liver specialists) regarding treatment options before initiating therapy (AAN [Farez 2019]). Patients should be screened for human papilloma virus as clinically necessary.

• Infusion reactions: [US Boxed Warning]: Serious and potentially fatal infusion-related reactions may occur; monitor for infusion reaction; carefully monitor during infusion; withhold treatment for serious or grade 3 or 4 infusion reactions. For B-CLL, gradual escalation to the recommended maintenance dose is required at initiation and with treatment interruptions (for ≥7 days) to minimize infusion-related reactions. For MS, must be administered in a setting with appropriate equipment and personnel to manage anaphylaxis or serious infusion reaction; monitor for 2 hours after each infusion; inform patients that serious infusion reactions may also occur after the 2-hour monitoring period. In patients treated for B-CLL, infusion reaction symptoms may include acute respiratory distress syndrome, anaphylactic/anaphylactoid shock, angioedema, bronchospasm, cardiac arrest, cardiac arrhythmias, chills, dyspnea, fever, hypotension, myocardial infarction, pulmonary infiltrates, rash, rigors, syncope, or urticaria. The incidence of infusion reaction is highest during the first week of B-CLL treatment. Premedicate with acetaminophen and an oral antihistamine. Medications for the treatment of reactions should be available for immediate use. Use caution and carefully monitor blood pressure in patients with ischemic heart disease and patients on antihypertensive therapy. For B-CLL, reinitiate with gradual dose escalation if treatment is withheld ≥7 days. Similar infusion reactions, as well as pulmonary alveolar hemorrhage, myocardial ischemia, myocardial infarction, cervicocephalic (eg, vertebral, carotid) arterial dissection, and life-threatening stroke (including ischemic and hemorrhagic stroke), have been observed with use in the treatment of multiple sclerosis; most cases occurred within 1 to 3 days. Cases of severe (including fatal) neutropenia have also been reported within 2 months of infusion; may resolve with granulocyte colony-stimulating factor treatment. Mild to moderate decreases in platelet counts at infusion initiation have been reported; may resolve without treatment. Premedication with corticosteroids for initial 3 days of each treatment course is recommended. Antihistamines and/or antipyretics may also be considered. Consider additional monitoring in patients with existing cardiovascular or respiratory compromise. Observe for infusion-related reactions; advise patients to monitor for signs/symptoms of infusion reaction, particularly during the 48 hours following infusion.

• Malignancy: [US Boxed Warning (Lemtrada)]: Alemtuzumab may cause an increased risk of malignancies, including thyroid cancer, melanoma, and lymphoproliferative disorders. Perform baseline and yearly skin exams. Other malignant neoplasm (breast cancer or basal cell carcinoma) has been observed (rarely) in patients receiving treatment for MS. Use caution if initiating treatment in patients with preexisting or ongoing malignancies.

• Pneumonitis: Pneumonitis (hypersensitivity or fibrosis) has been reported. Monitor for symptoms (dyspnea, cough, wheezing, hemoptysis, chest pain/tightness).

• Progressive multifocal leukoencephalopathy: Progressive multifocal leukoencephalopathy (PML) was diagnosed in a patient 2 months after the second alemtuzumab course for the treatment of MS. PML is an opportunistic viral infection of the brain caused by the John Cunningham (JC) virus and usually leads to death or severe disability. PML typically only occurs in patients who are immunocompromised; however, the patient who developed PML while taking alemtuzumab had no identifiable systemic medical condition resulting in immunosuppression, had not received other MS medications for >1 year, was not taking any concomitant immunomodulatory or immunosuppressant medications, and had not previously been treated with natalizumab. At the first sign or symptom suggestive of PML, perform a diagnostic evaluation and withhold therapy; symptoms progress over days to weeks and may include progressive weakness on one side of the body or clumsiness of limbs, vision disturbances, and mental status changes. Cases of PML have been diagnosed based on MRI findings and the detection of JC virus DNA in the cerebrospinal fluid without specific PML signs/symptoms. Monitoring with brain MRI for signs that may be consistent with PML may be beneficial and allow for an early diagnosis of PML.

• Stroke and cervicocephalic arterial dissection (Lemtrada): [US Boxed Warning (Lemtrada)]: Serious and life-threatening stroke (including ischemic and hemorrhagic stroke) has been reported within 3 days of Lemtrada administration. Instruct patients to seek immediate medical attention if symptoms of a stroke occur. Most cases of stroke occurred within 1 day of administration; cases of cervicocephalic (eg, vertebral, carotid) arterial dissection involving multiple arteries occurred within 3 days. Educate patients to seek immediate medical care if symptoms of stroke and cervicocephalic arterial dissection occur.

• Thrombotic thrombocytopenic purpura: TTP has been reported, and cases may include thrombocytopenia, microangiopathic hemolytic anemia, neurological symptoms, fever, and kidney impairment.

• Thyroid disorders: Autoimmune thyroid disorders occurred in over one-third of patients receiving alemtuzumab for MS. In a trial evaluating alemtuzumab versus interferon beta-1a in patients with MS, thyroid dysfunction occurred more frequently in patients taking alemtuzumab (34% versus 6.5%) (Daniels 2014). The incidence of the first episode of thyroid dysfunction increased annually the first 3 years (year 1: 4.6%; year 2: 13.3%; year 3: 16.1%) then gradually decreased thereafter. Among patients with alemtuzumab-related thyroid dysfunction, Graves hyperthyroidism occurred most commonly (23%), followed by hypothyroidism and subacute thyroiditis (7% and 4%, respectively). Thyroid dysfunction (thyroiditis, Graves disease, goiter) has also been reported with alemtuzumab use for the treatment of other conditions. For B-CLL treatment, thyroid-stimulating hormone (TSH) monitoring is recommended; monitor TSH at baseline and every 2 to 3 months during alemtuzumab treatment (Hamnvik 2011). For MS, monitor TSH at baseline and every 3 months until 48 months after last infusion or longer or at any time during therapy if clinically indicated or in case of pregnancy.

Dosage form specific issues:

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

Other warnings/precautions:

• Appropriate use: Alemtuzumab is not recommended for use in patients with MS with inactive disease or who are stable on other treatment. Patients should commit to at least 48 months of follow-up after the last infusion.

• Duplicate therapy: If considering Lemtrada treatment for use in a patient who has previously received Campath/MabCampath, consider the additive and long-lasting immune system effects.

• Immunizations: In the oncology setting, patients should not be immunized with live, viral vaccines during or recently after treatment. When using for the treatment of multiple sclerosis (MS), complete necessary immunizations at least 6 weeks prior to initiating alemtuzumab. Avoid live-attenuated vaccines in patients who currently receive or have recently discontinued alemtuzumab for MS; consider using live-attenuated vaccines only if risk of infection is high and killed vaccines are unavailable (AAN [Farez 2019]). The ability to respond to any vaccine following therapy is unknown. Testing for antibodies to varicella zoster virus (VZV) is recommended prior to initiation of alemtuzumab for non-oncology purposes if history of chickenpox or VZV vaccination status is unknown; consider vaccinations for antibody-negative patients and postpone alemtuzumab treatment for 6 weeks following VZV vaccination.

• REMS Program: [US Boxed Warning (Lemtrada)]: Due to the risk of autoimmunity, infusion reactions, and malignancies, alemtuzumab is available only through restricted distribution under a Risk Evaluation Mitigation Strategy (REMS) Program when used for the treatment of MS. Contact 1-855-676-6326 to enroll in the Lemtrada REMS program. Prescribers and pharmacies must be certified with the REMS program, and patients and healthcare facilities must be enrolled and comply with ongoing monitoring.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous [preservative free]:

Lemtrada: 12 mg/1.2 mL (1.2 mL) [contains edetate (edta) disodium dihydrate, polysorbate 80]

Generic Equivalent Available: US

No

Pricing: US

Solution (Lemtrada Intravenous)

12 mg/1.2 mL (per mL): $28,798.18

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Lemtrada: 12 mg/1.2 mL (1.2 mL) [contains edetate (edta) disodium dihydrate, polysorbate 80]

MabCampath: 30 mg/mL (1 mL) [contains edetate (edta) disodium dihydrate, polysorbate 80]

Prescribing and Access Restrictions

Campath is no longer commercially available in the United States; a restricted distribution program will allow access for appropriate patients. Information on necessary documentation and requirements is available from Clinigen Direct (1-877-768-4303) or https://www.clinigengroup.com/direct/en-gb/contact-us/#address-13.

Administration: Adult

IV: Campath or MabCampath [Canadian product]: Administer by IV infusion over 2 hours. Premedicate with diphenhydramine 50 mg and acetaminophen 500 to 1,000 mg 30 minutes before each infusion. IV glucocorticoids have been effective in decreasing severe infusion-related events. Start anti-infective prophylaxis. Other medications should not be added to or simultaneously infused through the same IV line. Do not give IV push or bolus. Compatible in polyvinylchloride (PVC) or polyethylene lined administration sets or low protein binding filters. May be given through peripheral IV.

Infusion times may have varied in studies for off-label uses; refer to specific reference citations.

Lemtrada: Administer by IV infusion over 4 hours (beginning within 8 hours after dilution); do not administer by IV push or IV bolus. May extend the infusion duration if clinically indicated. Do not infuse other medications through the same IV line. Premedicate with corticosteroids (methylprednisolone 1,000 mg or equivalent) for first 3 days of each treatment course. Administer in a setting with personnel and equipment appropriate to manage infusion reactions. Monitor vital signs prior to and periodically during the infusion. Infusion reactions should be managed symptomatically; consider discontinuing immediately for severe infusion reaction. Observe for at least 2 hours after each infusion, longer if clinically indicated.

SUBQ: Campath: SUBQ (off-label route): SUBQ administration has been studied (Ref); an increased rate of injection site reactions has been observed, with only rare incidences of chills or infusion-like reactions typically observed with IV infusion. A longer dose escalation time (1 to 2 weeks) may be needed due to injection site reactions (Lundin 2002). Premedicate with diphenhydramine 50 mg and acetaminophen 500 to 1,000 mg 30 minutes before dose. The subQ route should NOT be used for the treatment of T-PLL (Ref).

Alemtuzumab is associated with a moderate emetic potential in adults in the oncology setting; antiemetics may be recommended to prevent nausea and vomiting (Ref).

Administration: Pediatric

IV: Campath: Dilute prior to administration; begin administration within 8 hours of dilution; administer by IV infusion over 2 hours (Ref); do not give as an IV push or bolus injection. Compatible in polyvinylchloride (PVC) or polyethylene lined administration sets. Premedication with diphenhydramine and acetaminophen 30 minutes prior to infusion is recommended to help with infusion reaction. IV glucocorticoids have been effective in decreasing severe infusion-related events.

SubQ: Hemophagocytic lymphocytosis: Campath: Limited data available for subcutaneous administration (Ref). In adults, target dose was divided into 2 injection sites of 1.5 mL each (Ref). Premedicate with diphenhydramine and acetaminophen 30 minutes before dose.

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:

Lemtrada: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103948s5192lbl.pdf#page=30

Use: Labeled Indications

B-cell chronic lymphocytic leukemia: Campath or MabCampath [Canadian product]: Treatment (as a single agent) of B-cell chronic lymphocytic leukemia.

Multiple sclerosis, relapsing: Lemtrada: Treatment of relapsing-remitting and active secondary progressive multiple sclerosis (MS); generally reserved for patients who have had an inadequate response to ≥2 medications indicated for the treatment of MS.

Limitations of use: Alemtuzumab is not recommended for use in patients with clinically isolated syndrome due to its safety profile.

Use: Off-Label: Adult

Acute graft-versus-host disease (steroid refractory) (treatment); Aplastic anemia, refractory; Autoimmune hemolytic anemia, chronic lymphocytic leukemia–induced; Hematopoietic cell transplant (allogeneic) conditioning regimen and/or graft-versus-host disease prophylaxis; Hemophagocytic lymphohistiocytosis, refractory; Mycosis fungoides/Sézary syndrome (advanced); Solid organ transplantation: Heart transplant, induction; Solid organ transplantation: Intestine transplant, induction; Solid organ transplantation: Kidney transplant, induction; Solid organ transplantation: Kidney transplant, steroid-resistant cellular rejection; Solid organ transplantation: Lung transplant, induction; Solid organ transplantation: Lung transplant, refractory rejection, treatment; Solid organ transplantation: Multivisceral transplant, induction; Solid organ transplantation: Pancreas transplant, induction; T-cell large granular lymphocytic leukemia; T-cell prolymphocytic leukemia

Medication Safety Issues
High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes (chemotherapeutic agent, parenteral and oral) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Acute Care, Community/Ambulatory Care, and Long-Term Care Settings).

Other safety concerns:

Duplicate therapy issues: Campath and MabCampath contain alemtuzumab, which is the same ingredient contained in Lemtrada; patients receiving Lemtrada should not be treated with Campath or MabCampath.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk C: Monitor therapy

Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid combination

Anticoagulants: Alemtuzumab may enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. Risk C: Monitor therapy

Antithyroid Agents: Myelosuppressive Agents may enhance the neutropenic effect of Antithyroid Agents. Risk C: Monitor therapy

Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. Risk X: Avoid combination

BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. Risk X: Avoid combination

Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. Risk C: Monitor therapy

Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid combination

Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). Risk X: Avoid combination

Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents. Risk C: Monitor therapy

Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). Risk X: Avoid combination

Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. Risk X: Avoid combination

CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. Risk C: Monitor therapy

Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test. Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results. Risk D: Consider therapy modification

COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector). Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters). Risk D: Consider therapy modification

COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). Risk C: Monitor therapy

COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA). Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details. Risk D: Consider therapy modification

COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). Risk C: Monitor therapy

COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). Risk C: Monitor therapy

Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely. Risk D: Consider therapy modification

Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). Risk X: Avoid combination

Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid combination

Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents. Risk C: Monitor therapy

Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid combination

Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. Risk X: Avoid combination

Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid combination

Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. Risk C: Monitor therapy

Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored. Risk D: Consider therapy modification

Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents. Risk D: Consider therapy modification

Linezolid: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk C: Monitor therapy

Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Risk X: Avoid combination

Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. Risk X: Avoid combination

Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. Risk X: Avoid combination

Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. Risk C: Monitor therapy

Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. Risk C: Monitor therapy

Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. Risk C: Monitor therapy

Ozanimod: Alemtuzumab may enhance the immunosuppressive effect of Ozanimod. Risk X: Avoid combination

Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. Risk C: Monitor therapy

Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. Risk X: Avoid combination

Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. Risk C: Monitor therapy

Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Risk X: Avoid combination

Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider therapy modification

Ponesimod: May enhance the immunosuppressive effect of Alemtuzumab. Risk X: Avoid combination

Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk C: Monitor therapy

Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine. Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine. Risk D: Consider therapy modification

Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. Risk X: Avoid combination

Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b. Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects. Risk D: Consider therapy modification

Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents. Risk C: Monitor therapy

Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). Risk X: Avoid combination

Siponimod: Alemtuzumab may enhance the immunosuppressive effect of Siponimod. Risk X: Avoid combination

Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T. Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy. Risk D: Consider therapy modification

Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk C: Monitor therapy

Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). Risk X: Avoid combination

Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. Risk X: Avoid combination

Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. Risk X: Avoid combination

Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib. Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials. Risk X: Avoid combination

Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. Risk X: Avoid combination

Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. Risk C: Monitor therapy

Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. Risk X: Avoid combination

Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). Risk X: Avoid combination

Vaccines (Non-Live/Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Non-Live/Inactivated/Non-Replicating). Management: Give non-live/inactivated/non-replicating vaccines at least 2 weeks prior to starting immunosuppressants when possible. Patients vaccinated less than 14 days before or during therapy should be revaccinated at least 2 to 3 months after therapy is complete. Risk D: Consider therapy modification

Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. Risk X: Avoid combination

Reproductive Considerations

Evaluate pregnancy status prior to using Campath in patients who may become pregnant.

Patients who could become pregnant should use effective contraception during therapy and for at least 3 months after the last dose of Campath. Patients who could become pregnant should use effective contraception during therapy and for 4 months after the last dose of Lemtrada.

In general, disease-modifying therapies for multiple sclerosis are stopped prior to a planned pregnancy except in females at high risk of multiple sclerosis activity (AAN [Rae-Grant 2018]). Consider use of agents other than alemtuzumab for patients at high risk of disease reactivation who are planning to become pregnant. Delaying pregnancy is recommended for patients with persistent high disease activity; however, use of alemtuzumab may be an alternative option in these patients if the last infusion is at least 4 months prior to conception (ECTRIMS/EAN [Montalban 2018]).

Patients requiring alemtuzumab for multiple sclerosis and desiring pregnancy should have thyroid function testing prior conception and be euthyroid before attempting to become pregnant (Decallonne 2018; Hammerstad 2021).

Pregnancy Considerations

Alemtuzumab is a humanized monoclonal antibody (IgG1). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).

Outcome data following use of alemtuzumab in pregnant patients with multiple sclerosis are available (Alroughani 2016; Oh 2020; Tuohy 2015; Valeria 2021).

Alemtuzumab administration may result in the formation of autoantibodies, which may cross the placenta. A case report describes the development of maternal Graves disease following alemtuzumab therapy with placental transfer of anti-thyroid antibodies resulting in neonatal Graves disease. The patient became pregnant 8 months after a third dose of alemtuzumab for the treatment of multiple sclerosis. Maternal thyrotropin receptor stimulating antibodies (TRAb) were slightly elevated at conception and increased significantly during pregnancy. TRAb levels were also significantly elevated in the infant at birth. Symptoms of thyrotoxicosis were observed at 10 days of age in the newborn; thyroid function tests returned to normal after 3 weeks of treatment and normal growth and development were reported at 3 months of age (Hammerstad 2022). Thyroid disorders induced by alemtuzumab therapy may cause adverse maternal and fetal events.

In general, disease-modifying therapies for multiple sclerosis are not initiated during pregnancy, except in patients at high risk of multiple sclerosis activity (AAN [Rae-Grant 2018]).

Data collection to monitor pregnancy and infant outcomes following exposure to alemtuzumab is ongoing. Health care providers are encouraged to enroll patients exposed to alemtuzumab during pregnancy in the pregnancy exposure registry (1-800-745-4447, option 2).

Breastfeeding Considerations

It is not known if alemtuzumab is present in breast milk.

Alemtuzumab is a humanized monoclonal antibody (IgG1). Human IgG is present in breast milk; concentrations are dependent upon IgG subclass and postpartum age (Anderson 2021).

According to the manufacturer, the decision to breastfeed during Lemtrada therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, benefits of treatment to the mother, and the long half-life of alemtuzumab. Other sources do not recommend breastfeeding during therapy (Dobson 2019; Fragoso 2018). Due to the potential for adverse reactions, including reduced lymphocyte counts in a breastfed child, the manufacturer does not recommend breastfeeding during Campath therapy or for at least 3 months after the last Campath dose.

Monitoring Parameters

Campath: CBC with differential and platelets (weekly, more frequent if worsening); signs and symptoms of infection; CD4+ lymphocyte counts (after treatment until recovery); cytomegalovirus antigen (routinely during and for 2 months after treatment); consider thyroid-stimulating hormone (TSH) at baseline and then every 2 to 3 months during alemtuzumab treatment (Hamnvik 2011). Monitor closely for infusion reactions (including hypotension, rigors, fever, shortness of breath, bronchospasm, chills, and/or rash); vital signs (prior to and during infusion); carefully monitor BP, especially in patients with ischemic heart disease or on antihypertensive medications. Advise patients to monitor for signs/symptoms of infusion reaction, particularly during the 48 hours following infusion. The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up. Evaluate pregnancy status prior to use in patients who could become pregnant. Monitor for signs/symptoms of infection; monitor for cytomegalovirus infection (during and for at least 2 months after completion of therapy). Monitor for signs/symptoms of autoimmune anemia or autoimmune thrombocytopenia.

Lemtrada: CBC with differential prior to initiation then monthly until 48 months after last infusion; serum creatinine prior to initiation then monthly until 48 months after last infusion or at any time during therapy if clinically indicated; serum transaminases and total bilirubin prior to initiation then periodically until 48 months after the last infusion or at any time during therapy if clinically indicated; urinalysis with urine cell counts prior to initiation then monthly until 48 months after last infusion (urine dipstick results of ≥1+ protein warrant assessment of urine protein to creatinine ratio); urine protein to creatinine ratio at baseline and then as clinically indicated (evaluate further for nephropathies if urine protein to creatinine ratio >200 mg/g, increase in serum creatinine >30%, or unexplained hematuria); ECG at baseline; TSH at baseline and every 3 months until 48 months after last infusion or longer or at any time during therapy if clinically indicated or in case of pregnancy; coagulopathy panel, including aPTT, in patients presenting with signs of acquired hemophilia A. Observe for at least 2 hours after each infusion, longer if clinically indicated. Monitor for signs/symptoms of infection; annual human papillomavirus screening; latent infection screening (eg, hepatitis, tuberculosis) in high-risk populations or in countries with high tuberculosis burden (baseline); signs/symptoms of progressive multifocal leukoencephalopathy and hemophagocytic lymphohistiocytosis; signs/symptoms of thrombotic thrombocytopenic purpura; signs and symptoms of autoimmune encephalitis; baseline and annual skin exams (for melanoma).

Mechanism of Action

Alemtuzumab binds to CD52, a nonmodulating antigen present on the surface of B and T lymphocytes, a majority of monocytes, macrophages, NK cells, and a subpopulation of granulocytes. After binding to CD52+ cells, an antibody-dependent lysis of malignant cells occurs. In multiple sclerosis, alemtuzumab immunomodulatory effects may include alteration in the number, proportions, and properties of some lymphocyte subsets following treatment.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Vd: IV: Campath: 0.18 L/kg (range: 0.1 to 0.4 L/kg); Lemtrada: 14.1 L

Metabolism: Campath: Clearance decreases with repeated dosing (due to loss of CD52 receptors in periphery), resulting in a sevenfold increase in AUC after 12 weeks of therapy.

Half-life elimination: IV: Campath: 11 hours (following first 30 mg dose; range: 2 to 32 hours); 6 days (following the last 30 mg dose; range: 1 to 14 days); Lemtrada: ~2 weeks

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Lemtrada | Mabcampath;
  • (AR) Argentina: Lemtrada;
  • (AT) Austria: Lemtrada | Mabcampath;
  • (AU) Australia: Lemtrada;
  • (BE) Belgium: Campath | Lemtrada;
  • (BG) Bulgaria: Lemtrada;
  • (BR) Brazil: Lemtrada;
  • (CH) Switzerland: Lemtrada | Mabcampath;
  • (CL) Chile: Lemtrada;
  • (CO) Colombia: Lemtrada;
  • (CZ) Czech Republic: Campath | Lemtrada;
  • (DE) Germany: Lemtrada | Mabcampath;
  • (DO) Dominican Republic: Lemtrada;
  • (EC) Ecuador: Lemtrada;
  • (EE) Estonia: Campath | Lemtrada | Mabcampath;
  • (EG) Egypt: Lemtrada;
  • (ES) Spain: Lemtrada | Mabcampath;
  • (FI) Finland: Lemtrada | Mabcampath;
  • (FR) France: Lemtrada | Mabcampath;
  • (GB) United Kingdom: Lemtrada | Mabcampath;
  • (GR) Greece: Lemtrada;
  • (HK) Hong Kong: Lemtrada;
  • (HR) Croatia: Lemtrada | Mabcampath;
  • (HU) Hungary: Lemtrada | Mabcampath;
  • (IE) Ireland: Lemtrada;
  • (IT) Italy: Lemtrada | Mabcampath;
  • (JP) Japan: Mabcampath;
  • (KR) Korea, Republic of: Lemtrada;
  • (KW) Kuwait: Lemtrada;
  • (LB) Lebanon: Lemtrada;
  • (LT) Lithuania: Campath | Lemtrada | Mabcampath;
  • (LV) Latvia: Lemtrada | Mabcampath;
  • (MX) Mexico: Lemtrada;
  • (MY) Malaysia: Lemtrada | Mabcampath;
  • (NL) Netherlands: Lemtrada;
  • (NO) Norway: Lemtrada;
  • (PE) Peru: Lemtrada;
  • (PL) Poland: Lemtrada | Mabcampath;
  • (PR) Puerto Rico: Campath | Lemtrada;
  • (PT) Portugal: Lemtrada | Mabcampath;
  • (PY) Paraguay: Lemtrada;
  • (QA) Qatar: Lemtrada;
  • (RO) Romania: Lemtrada | Mabcampath;
  • (RU) Russian Federation: Campath | Lemtrada;
  • (SA) Saudi Arabia: Lemtrada;
  • (SE) Sweden: Lemtrada | Mabcampath;
  • (SG) Singapore: Lemtrada | Mabcampath;
  • (SI) Slovenia: Campath | Lemtrada | Mabcampath;
  • (SK) Slovakia: Lemtrada;
  • (TH) Thailand: Lemtrada;
  • (TW) Taiwan: Lemtrada | Mabcampath;
  • (UA) Ukraine: Lemtrada | Mabcampath;
  • (ZA) South Africa: Lemtrada | Mabcampath
  1. Abu-Elmagd KM, Costa G, Bond GJ, et al. Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. Ann Surg. 2009;250(4):567-581. doi:10.1097/SLA.0b013e3181b67725 [PubMed 19730240]
  2. Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. [PubMed 3960626]
  3. Alroughani R, Altintas A, Al Jumah M, et al. Pregnancy and the use of disease-modifying therapies in patients with multiple sclerosis: benefits versus risks. Mult Scler Int. 2016;2016:1034912. doi:10.1155/2016/1034912 [PubMed 28078140]
  4. Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110 [PubMed 33956488]
  5. Bank JR, Heidt S, Moes DJ, et al. Alemtuzumab induction and delayed acute rejection in steroid-free simultaneous pancreas-kidney transplant recipients. Transplant Direct. 2016;3(1):e124. doi:10.1097/TXD.0000000000000634 [PubMed 28349124]
  6. Basu A, Ramkumar M, Tan HP, et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc. 2005;37(2):923-926. doi: 10.1016/j.transproceed.2004.12.019 [PubMed 15848576]
  7. Benazzo A, Auner S, Boehm PM, et al. Outcomes with alemtuzumab induction therapy in lung transplantation: a comprehensive large-scale single-center analysis. Transpl Int. 2021;34(12):2633-2643. doi:10.1111/tri.14153 [PubMed 34738249]
  8. Berger JR, Houff S. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann Neurol. 2009;65(4):367-377. doi: 10.1002/ana.21630. [PubMed 19399841]
  9. Bubalo J, Carpenter PA, Majhail N, et al; American Society for Blood and Marrow Transplantation practice guideline committee. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Biol Blood Marrow Transplant. 2014;20(5):600-616. doi: 10.1016/j.bbmt.2014.01.019. [PubMed 24462742]
  10. Campath (alemtuzumab) [prescribing information]. Cambridge, MA: Genzyme Corporation; April 2023.
  11. Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm. [PubMed 6423951]
  12. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation. 2005;80(4):457-465. [PubMed 16123718]
  13. Clatworthy MR, Sivaprakasam R, Butler AJ, Watson CJ. Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation. Transplantation. 2007;84(12):1563-1567. doi:10.1097/01.tp.0000295718.55669.3a [PubMed 18165765]
  14. Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. Front Immunol. 2020;11:1920. doi:10.3389/fimmu.2020.01920 [PubMed 33013843]
  15. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012;78(14):1069-1078. doi: 10.1212/WNL.0b013e31824e8ee7. [PubMed 22442431]
  16. Coles AJ, Compston DA, Selmaj KW, et al; CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-1801. doi: 10.1056/NEJMoa0802670. [PubMed 18946064]
  17. Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood. 2011;118(24):6299-6305. doi: 10.1182/blood-2011-08-371138. [PubMed 21960587]
  18. Daniels GH, Vladic A, Brinar V, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab. 2014;99(1):80-89. doi: 10.1210/jc.2013-2201. [PubMed 24170099]
  19. Dearden CE, Johnson R, Pettengell R, et al; British Committee for Standards in Haematology. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol. 2011;153(4):451-485. doi: 10.1111/j.1365-2141.2011.08651.x. [PubMed 21480860]
  20. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98(6):1721-1726. [PubMed 11535503]
  21. Decallonne B, Bartholomé E, Delvaux V, et al. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management. Acta Neurol Belg. 2018;118(2):153-159. doi:10.1007/s13760-018-0883-2 [PubMed 29372482]
  22. Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. Pract Neurol. 2019;19(2):106-114. doi: 10.1136/practneurol-2018-002060. [PubMed 30612100]
  23. Dumitriu B, Ito S, Feng X, et al. Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study. Lancet Haematol. 2016;3(1):e22-e29. [PubMed 26765645]
  24. Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2013;60(7):1073-1082. doi: 10.1002/pbc.24508. [PubMed 23512831]
  25. Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2011;57(2):191-198. doi: 10.1002/pbc.23114. [PubMed 21465637]
  26. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103(8):2920-2924. doi: 10.1182/blood-2003-10-3389 [PubMed 15070664]
  27. Ensor CR, Rihtarchik LC, Morrell MR, et al. Rescue alemtuzumab for refractory acute cellular rejection and bronchiolitis obliterans syndrome after lung transplantation. Clin Transplant. 2017;31(4). doi:10.1111/ctr.12899 [PubMed 28008661]
  28. Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2019;93(13):584-594. doi:10.1212/WNL.0000000000008157 [PubMed 31462584]
  29. Farney A, Sundberg A, Moore P, et al. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant. 2008;22(1):41-49. doi: 10.1111/j.1399-0012.2007.00742.x. [PubMed 18217904]
  30. FDA Safety Alert. MedWatch. FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab). Food and Drug Administration website. https://www.fda.gov/Drugs/DrugSafety/ucm624247.htm. Accessed November 30, 2018.
  31. Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003;98(4):773-778. doi: 10.1002/cncr.11551. [PubMed 12910522]
  32. Fragoso YD, Adoni T, Brooks JBB, et al. Practical evidence-based recommendations for patients with multiple sclerosis who want to have children. Neurol Ther. 2018;7(2):207-232. doi: 10.1007/s40120-018-0110-3. [PubMed 30167914]
  33. Furuya Y, Jayarajan SN, Taghavi S, et al. The impact of alemtuzumab and basiliximab induction on patient survival and time to bronchiolitis obliterans syndrome in double lung transplantation recipients. Am J Transplant. 2016;16(8):2334-2341. doi:10.1111/ajt.13739 [PubMed 26833657]
  34. Hale G, Rebello P, Brettman LR, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood. 2004;104(4):948-955. doi: 10.1182/blood-2004-02-0593. [PubMed 15090452]
  35. Hammerstad SS, Celius EG, Husby H, Sørensen IM, Norheim IE. Management of severe Graves' hyperthyroidism in pregnancy following immune reconstitution therapy in multiple sclerosis. J Endocr Soc. 2021;5(6):bvab044. doi:10.1210/jendso/bvab044 [PubMed 34017934]
  36. Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst. 2011;103(21):1572-1587. doi: 10.1093/jnci/djr373. [PubMed 22010182]
  37. Hanaway MJ, Woodle ES, Mulgaonkar S, et al; INTAC Study Group. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364(20):1909-1919. doi: 10.1056/NEJMoa1009546. [PubMed 21591943]
  38. Haynes R, Harden P, Judge P, et al; 3C Study Collaborative Group. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet. 2014;384(9955):1684-1690. doi:10.1016/S0140-6736(14)61095-3 [PubMed 25078310]
  39. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296 [PubMed 32658626]
  40. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25(35):5616-5623. doi: 10.1200/JCO.2007.12.9098. [PubMed 17984186]
  41. Hopfinger G, Busch R, Pflug N, et al. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. Cancer. 2013;119(12):2258-2267. doi:10.1002/cncr.27972 [PubMed 23512246]
  42. Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757 [PubMed 32716741]
  43. Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313. [PubMed 12534540]
  44. Jaksch P, Ankersmit J, Scheed A, et al. Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study. Am J Transplant. 2014;14(8):1839-1845. doi:10.1111/ajt.12824 [PubMed 25039364]
  45. Kanda J, Lopez RD, Rizzieri DA. Alemtuzumab for the prevention and treatment of graft-versus-host disease. Int J Hematol. 2011;93(5):586-593. doi: 10.1007/s12185-011-0802-2. [PubMed 21369856]
  46. Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia. 2007;21(3):511-514. doi: 10.1038/sj.leu.2404512 [PubMed 17215854]
  47. Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results. Am J Transplant. 2006;6(2):331-339. doi:10.1111/j.1600-6143.2005.01166.x [PubMed 16426317]
  48. Keating MJ, Cazin B, Coutré S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20(1):205-213. doi: 10.1200/JCO.2002.20.1.205. [PubMed 11773171]
  49. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554-3561. [PubMed 11986207]
  50. Kennedy B, Hillmen P. Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL. Med Oncol. 2002;19 (suppl):S49-S55. [PubMed 12180492]
  51. Kimura T, Lauro A, Cescon M, et al. Impact of induction therapy on bacterial infections and long-term outcome in adult intestinal and multivisceral transplantation: a comparison of two different induction protocols: daclizumab vs. alemtuzumab. Clin Transplant. 2009;23(3):420-425. doi:10.1111/j.1399-0012.2008.00922.x [PubMed 19537304]
  52. Lauro A, Amaduzzi A, Dazzi A, et al. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: a comparison of two different regimens on 29 recipients during the early post-operative period. Dig Liver Dis. 2007a;39(3):253-256. doi:10.1016/j.dld.2006.11.012 [PubMed 17275428]
  53. Lauro A, Zanfi C, Bagni A, et al. Induction therapy in adult intestinal transplantation: reduced incidence of rejection with "2-dose" alemtuzumab protocol. Clin Transplant. 2013;27(4):567-570. doi:10.1111/ctr.12166 [PubMed 23815302]
  54. Lauro A, Zanfi C, Ercolani G, et al. Twenty-five consecutive isolated intestinal transplants in adult patients: a five-yr clinical experience. Clin Transplant. 2007b;21(2):177-185. doi:10.1111/j.1399-0012.2007.00620.x [PubMed 17425742]
  55. Lemtrada (alemtuzumab) [prescribing information]. Cambridge, MA: Genzyme Corporation; August 2022.
  56. Lemtrada (alemtuzumab) [prescribing information]. Cambridge, MA: Genzyme Corporation; May 2023.
  57. Lemtrada (alemtuzumab) [prescribing information]. Cambridge, MA: Genzyme Corporation; January 2024.
  58. Lemtrada (alemtuzumab) [product monograph]. Toronto, Ontario, Canada: Sanofi-Aventis Canada Inc; April 2024.
  59. Lepretre S, Aurran T, Mahé B, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012;119(22):5104-5110. doi: 10.1182/blood-2011-07-365437. [PubMed 22337714]
  60. Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.
  61. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101(11):4267-4272. doi: 10.1182/blood-2002-09-2802. [PubMed 12543862]
  62. Lundin J, Kimby E, Björkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100(3):768-773. doi: 10.1182/blood-2002-01-0159. [PubMed 12130484]
  63. Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol. 1998;16(10):3257-3263. doi: 10.1200/JCO.1998.16.10.3257. [PubMed 9779699]
  64. MabCampath (alemtuzumab) [product monograph]. Toronto, Ontario, Canada: Sanofi-Aventis Canada Inc; April 2024.
  65. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int. 2006;19(9):705-714. doi: 10.1111/j.1432-2277.2006.00343.x. [PubMed 16918530]
  66. Marcos A, Eghtesad B, Fung JJ, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation. 2004;78(7):966-971. [PubMed 15480160]
  67. Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne RY. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am J Transplant. 2008(7):1480-1485. doi: 10.1111/j.1600-6143.2008.02273.x. [PubMed 18510632]
  68. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60(1):101-109. doi: 10.1002/pbc.24188. [PubMed 22522603]
  69. Martínez C, Solano C, Ferrá C, Sampol A, Valcárcel D, Pérez-Simón JA; Spanish Group for Stem Cell Transplantation (Grupo Español de Trasplante Hemopoyético y Terapia Celular). Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study. Biol Blood Marrow Transplant. 2009;15(5):639-642. doi: 10.1016/j.bbmt.2009.01.014. [PubMed 19361757]
  70. Mead AJ, Thomson KJ, Morris EC, et al. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood. 2010;115(25):5147-5153. doi: 10.1182/blood-2010-01-265413. [PubMed 20371745]
  71. Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis [published correction appears in Eur J Neurol. 2018;25(3):605]. Eur J Neurol. 2018;25(2):215-237. doi: 10.1111/ene.13536 [PubMed 29352526]
  72. Muthusamy AS, Vaidya AC, Sinha S, Roy D, Elker DE, Friend PJ. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. Am J Transplant. 2008;8(10):2126-131. doi:10.1111/j.1600-6143.2008.02373.x [PubMed 18828772]
  73. Nishida S, Levi DM, Moon JI, et al. Intestinal transplantation with alemtuzumab (Campath-1H) induction for adult patients. Transplant Proc. 2006;38(6):1747-1749. doi:10.1016/j.transproceed.2006.05.057 [PubMed 16908270]
  74. Oh J, Achiron A, Celius EG, et al; CAMMS223, CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. Mult Scler Relat Disord. 2020;43:102146. doi:10.1016/j.msard.2020.102146 [PubMed 32498033]
  75. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997;15(4):1567-1574. doi: 10.1200/JCO.1997.15.4.1567. [PubMed 9193354]
  76. Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol. 1996;93(1):151-153. [PubMed 8611450]
  77. Osterborg A, Karlsson C, Lundin J. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2009;4(1):47-53. doi: 10.1007/s11899-009-0007-4. [PubMed 20425438]
  78. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646. doi: 10.1155/2012/985646 [PubMed 22235228]
  79. Pascual J, Pirsch JD, Odorico JS, et al. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. Transplantation. 2009;87(1):125-132. doi:10.1097/TP.0b013e31818c6db0 [PubMed 19136902]
  80. Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol. 1997;15(7):2667-2672. doi: 10.1200/JCO.1997.15.7.2667. [PubMed 9215839]
  81. Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol. 2009;86(4):328-344. doi:10.1002/bdrb.20201 [PubMed 19626656]
  82. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology [published correction appears in Neurology. 2019;92(2):112]. Neurology. 2018;90(17):777-788. doi: 10.1212/WNL.0000000000005347. [PubMed 29686116]
  83. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20(18):3891-3897. doi: 10.1200/JCO.2002.06.119 [PubMed 12228210]
  84. Reams BD, Musselwhite LW, Zaas DW, et al. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant. 2007;7(12):2802-2808. doi:10.1111/j.1600-6143.2007.02000.x [PubMed 17924993]
  85. Risitano AM, Selleri C, Serio B, et al; Working Party Severe Aplastic Anaemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT). Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol. 2010;148(5):791-796. doi: 10.1111/j.1365-2141.2009.08027.x. [PubMed 19995389]
  86. Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270. [PubMed 27664248]
  87. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Wu CO, Young NS. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood. 2012;119(2):345-354. doi: 10.1182/blood-2011-05-352328. [PubMed 22067384]
  88. Schnitzler M, Hasskarl J, Egger M, Bertz H, Finke J. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab [published correction appears in Biol Blood Marrow Transplant. 2010;16(1):128.]. Biol Blood Marrow Transplant. 2009;15(8):910-918. doi: 10.1016/j.bbmt.2009.04.002. [PubMed 19589480]
  89. Schweighofer CD, Ritgen M, Eichhorst BF, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol. 2009;144(1):95-98. doi: 10.1111/j.1365-2141.2008.07394.x. [PubMed 19016732]
  90. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313. [PubMed 7746084]
  91. Shyu S, Dew MA, Pilewski JM, et al. Five-year outcomes with alemtuzumab induction after lung transplantation. J Heart Lung Transplant. 2011;30(7):743-754. doi:10.1016/j.healun.2011.01.714 [PubMed 21420318]
  92. Stilgenbauer S, Zenz T, Winkler D, et al; German Chronic Lymphocytic Leukemia Study Group. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009;27(24):3994-4001. doi: 10.1200/JCO.2008.21.1128. [PubMed 19597025]
  93. Teuteberg JJ, Shullo MA, Zomak R, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant. 2010;10(2):382-388. doi: 10.1111/j.1600-6143.2009.02856.x [PubMed 19889126]
  94. Thai NL, Khan A, Tom K, et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: one- and two-year outcomes. Transplantation. 2006;82(12):1621-1624. doi:10.1097/01.tp.0000250712.12389.3d [PubMed 17198247]
  95. Treon SP, Soumerai JD, Hunter ZR, et al. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood. 2011;118(2):276-281. doi: 10.1182/blood-2011-02-338558. [PubMed 21566092]
  96. Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 2015;86(2):208-215. doi:10.1136/jnnp-2014-307721 [PubMed 24849515]
  97. Tzakis AG, Kato T, Nishida S, et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation. 2003;75(9):1512-1517. doi:10.1097/01.TP.0000060250.50591.39 [PubMed 12792506]
  98. Tzakis AG, Kato T, Nishida S, et al. Campath-1H in intestinal and multivisceral transplantation: preliminary data. Transplant Proc. 2002;34(3):937. doi:10.1016/s0041-1345(02)02679-9 [PubMed 12034248]
  99. Uemura T, Ramprasad V, Matsushima K, et al Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. Transplantation. 2011;92(6):678-685. doi:10.1097/TP.0b013e31822b58be [PubMed 21841541]
  100. Valeria RC, Roberta L, Francesco S, Marcello M, Antonio C, Vincenzo BM. Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series. Neurol Sci. 2021;42(8):3427-3430. doi:10.1007/s10072-020-04975-5 [PubMed 33860394]
  101. van Besien K, Artz A, Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5728-5738. doi: 10.1200/JCO.2005.15.602. [PubMed 16009946]
  102. van Besien K, Kunavakkam R, Rondon G, et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009;15(5):610-617. doi: 10.1016/j.bbmt.2009.01.021. [PubMed 19361753]
  103. van den Hoogen MW, Hesselink DA, van Son WJ, Weimar W, Hilbrands LB. Treatment of steroid-resistant acute renal allograft rejection with alemtuzumab. Am J Transplant. 2013;13(1):192-196. doi: 10.1111/j.1600-6143.2012.04328.x [PubMed 23167538]
  104. Vianna R, Farag A, Gaynor JJ, et al. Association of more intensive induction with less acute rejection following intestinal transplantation: results of 445 consecutive cases from a single center. Transplantation. 2020a;104(10):2166-2178. doi:10.1097/TP.0000000000003074 [PubMed 31929425]
  105. Vianna R, Farag A, Gaynor JJ, et al. Association of alemtuzumab induction with a significantly lower incidence of GVHD following intestinal transplantation: results of 445 consecutive cases from a single center. Transplantation. 2020b;104(10):2179-2188. doi:10.1097/TP.0000000000003111 [PubMed 31929428]
  106. Vo AA, Wechsler EA, Wang J, et al. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant. 2008;8(1):144-149. doi: 10.1111/j.1600-6143.2007.02017.x. [PubMed 17973966]
  107. Whited LK, Latran MJ, Hashmi ZA, et al. Evaluation of alemtuzumab versus basiliximab induction: a retrospective cohort study in lung transplant recipients. Transplantation. 2015;99(10):2190-2195. doi:10.1097/TP.0000000000000687 [PubMed 25769073]
  108. Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114(4):891-898. [PubMed 11564082]
  109. Wolff D, Schleuning M, von Harsdorf S, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(1):1-17. doi: 10.1016/j.bbmt.2010.05.011 [PubMed 20685255]
  110. Zachariah M, Gregg A, Schold J, Magliocca J, Kayler LK. Alemtuzumab induction in simultaneous pancreas and kidney transplantation. Clin Transplant. 2013;27(5):693-700. doi:10.1111/ctr.12199 [PubMed 23924066]
Topic 8725 Version 355.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟